financetom
Business
financetom
/
Business
/
Daiwa Previews This Week's Bank of Japan Policy Meeting, Macroeconomic Data
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Daiwa Previews This Week's Bank of Japan Policy Meeting, Macroeconomic Data
Jul 29, 2024 4:29 AM

07:00 AM EDT, 07/29/2024 (MT Newswires) -- The Bank of Japan's (BoJ) policy announcement -- due out at 10:30 p.m. ET Tuesday -- is more uncertain than the United States Federal Reserve's one of Wednesday, said Daiwa Capital Markets.

In part due to the yen's (JPY) marked appreciation since the ministry of finance's (MoF) foreign exchange intervention earlier this month, the softness of consumption and recent moderation in underlying inflation pressures, Daiwa suspects the BoJ will keep the interest rate on excess reserves unchanged at 0.1%.

However, the BoJ will unveil its plans for quantitative tightening (QT) over the next two years, stated the bank. In keeping with Governor Kazuo Ueda's relatively cautious approach to policymaking, Daiwa expects the BoJ's monthly average pace of gross Japanese government bond (JGB) purchases to be halved over the next two years from the current rate of six trillion yen per month, perhaps with an initial reduction of just 500 billion yen in monthly purchases over the coming quarter.

The Policy Board will also publish updated economic projections, added the bank.

In terms of economic data, Japan's industrial production (IP) figures (at 7:50 p.m. ET on Tuesday) are expected to report a notable decline in June (4.5% m/m contraction) as further temporary factory shutdowns on safety concerns impacted the autos sector. This notwithstanding, manufacturing output will still post a decline increase of around 2.5% three-month/three-month, although reversing only part of the 5.1% slump in Q1.

Meanwhile, June labor market and retail sales numbers are also due (overnight Monday and overnight Tuesday respectively).

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Nike cutting jobs at European headquarters in the Netherlands -Bloomberg
Nike cutting jobs at European headquarters in the Netherlands -Bloomberg
Jun 5, 2024
AMSTERDAM, June 5 (Reuters) - Nike ( NKE ) is cutting jobs at its European headquarters in the Dutch city Hilversum, Bloomberg reported late on Tuesday. Nike ( NKE ) did not immediately reply to an emailed request for comment. According to the sportswear giant's website, more than 2,000 employees work at its European headquarters. It is not clear how...
Market Chatter: eBay to Reportedly Drop American Express Card Amid Fee Dispute
Market Chatter: eBay to Reportedly Drop American Express Card Amid Fee Dispute
Jun 5, 2024
04:53 AM EDT, 06/05/2024 (MT Newswires) -- eBay ( EBAY ) will stop taking American Express ( AXP ) cards as a payment method from Aug. 17 due to unacceptably high fees for processing credit card transactions, Bloomberg News reported Wednesday citing an email that the company plans to send to its online marketplace customers this week. The two companies...
No more chicken Big Macs - EU court rules against McDonald's in trademark case
No more chicken Big Macs - EU court rules against McDonald's in trademark case
Jun 5, 2024
BRUSSELS, June 5 (Reuters) - U.S. fast-food chain McDonald's does not have the right to use the term Big Mac for poultry products after it had not used it for them for five consecutive years, Europe's second top court said on Wednesday, in a partial win for Irish rival Supermac's in a long-running trademark dispute. The Luxembourg-based General Court's ruling...
Gilead Sciences Says Investigational Chronic Liver Disease Drug Shows 'Sustained Efficacy' in Long-Term Trial
Gilead Sciences Says Investigational Chronic Liver Disease Drug Shows 'Sustained Efficacy' in Long-Term Trial
Jun 5, 2024
04:46 AM EDT, 06/05/2024 (MT Newswires) -- Gilead Sciences ( GILD ) said Wednesday investigational drug seladelpar for the treatment of primary biliary cholangitis showed sustained efficacy in a two-year interim analysis of a long-term phase 3 trial. Primary biliary cholangitis is a chronic inflammatory liver disease characterized by impaired bile flow and the accumulation of toxic bile acids in...
Copyright 2023-2026 - www.financetom.com All Rights Reserved